The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension
Why the study?
Does bosentan reduce blood pressure in patients with mild-to-moderate essential hypertension?
Population
293 patients with mild-to-moderate essential hypertension
Comparison
Bosentan oral for four weeks vs Placebo or enalapril for four weeks
Design
RCT, randomly assigned
Follow-up
four weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports endothelin-receptor blockade for BP lowering in essential hypertension; extends options to a novel pathway beyond ACE inhibition.
Structured PICO
Does bosentan reduce blood pressure in patients with mild-to-moderate essential hypertension?
P
Population
293 patients with mild-to-moderate essential hypertension
I
Intervention
Bosentan oral (100, 500, or 1000 mg once daily or 1000 mg twice daily) for four weeks
C
Comparator
Placebo or enalapril (20 mg once daily) for four weeks
O
Outcome
Blood pressure measured before and after treatmentsurrogate
The endothelin-receptor antagonist bosentan significantly lowers blood pressure in essential hypertension without reflexive neurohormonal activation.
Cite This Study
Krum et al. (1998) studied this question.